Milestone Scientific Expanded Sales and Reimbursement Reach
The company added medical sales staff and increased access to Medicare billing to drive adoption of its CompuFlo system.
Updated on Sept. 29, 2026 in Public Companies
Live Poll
Do you trust that new medical technology business expansions lead to better care for your household?
Milestone Scientific has expanded its commercial infrastructure, including adding three dedicated medical sales professionals and 15 consultants to promote its CompuFlo medical technology. These moves aim to accelerate market penetration and support recurring revenue through improved reimbursement access.
Why it matters
Expanding reimbursement pathways and sales resources is critical for medical device companies seeking to transition proprietary technology from specialty clinical use to broader adoption. This effort specifically targets increasing physician utilization and establishing a repeatable geographic growth model.
The company reported 180 epidural feedback submissions through September 2026, while securing $325 in Medicare payment per procedure under CPT Category III code 0777T. The expansion utilizes a force of 18 sales personnel across more than 40 academic medical centers.
The players
Milestone Scientific
A developer of computerized drug delivery and medical technologies traded on the NYSE American under the ticker MLSS.
Avania Medical LLC
A firm specializing in clinical research, regulatory, and reimbursement consulting services for medical device manufacturers.
The details
Milestone Scientific is leveraging a combination of clinical data and reimbursement support to de-risk adoption for practitioners. By partnering with Avania Medical LLC, the company is facilitating billing compliance for providers using its CompuFlo system. This commercial model is designed to build recurring revenue through disposables by standardizing the workflow in academic and clinical settings.
Timeline
September 2026: The company reported Advisor Program feedback data totals.
Market Landscape
The strategy to utilize CPT Category III billing code 0777T reflects a standard industry pathway for securing long-term reimbursement for innovative medical procedures. By building volume through academic centers, the company is attempting to satisfy the data requirements necessary for a permanent Category I designation.
Operators in the medical device space should monitor the company's progress on transitioning its current billing code from Category III to Category I, as this shift would fundamentally change the reimbursement environment. Additionally, management should track how clinical studies from academic centers, such as those at the University of Texas, influence competitive positioning.
The takeaway
Commercial success for medical technology often hinges on moving a device from a clinical research tool to a reimbursed standard of care. Operators should track the conversion rates of Category III billing codes as a primary indicator of whether an innovation is gaining sustainable market traction.
Further reading
For broader trends in medical device commercialization, visit Public Companies.
More information
For more information on the company's clinical programs, visit the Company official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that new medical technology business expansions lead to better care for your household?
